Chinese Expert Consensus on the Whole-Course Management of Hepatocellular Carcinoma (2023 Edition)

被引：0

作者：

Yang, Yu ^{[1
,2
]}

Sun, Juxian ^{[3
]}

Cai, Jianqiang ^{[4
]}

Chen, Minshan ^{[5
]}

Dai, Chaoliu ^{[6
]}

Wen, Tianfu ^{[7
,8
]}

Xia, Jinglin ^{[9
]}

Ying, Mingang ^{[10
]}

Zhang, Zhiwei ^{[11
]}

Zhang, Xuewen ^{[12
]}

Fang, Chihua ^{[13
]}

Shen, Feng ^{[14
]}

An, Ping ^{[15
]}

Cai, Qingxian ^{[16
]}

Cao, Jingyu ^{[17
]}

Zeng, Zhen ^{[18
]}

Chen, Gang ^{[19
]}

Chen, Juan ^{[20
]}

Chen, Ping ^{[21
]}

Chen, Yongshun ^{[22
]}

Shan, Yunfeng ^{[19
]}

Dang, Shuangsuo ^{[23
]}

Guo, Wei-Xing ^{[3
]}

He, Jiefeng ^{[24
]}

Hu, Heping ^{[25
]}

Huang, Bin ^{[20
]}

Jia, Weidong ^{[26
]}

Jiang, Kexiang ^{[27
]}

Jin, Yan ^{[28
]}

Jin, Yongdong ^{[29
]}

Jin, Yun ^{[28
,31
]}

Li, Gong ^{[30
]}

Liang, Yun

Liu, Enyu ^{[32
]}

Liu, Hao ^{[33
]}

Peng, Wei ^{[7
,8
]}

Peng, Zhenwei ^{[34
]}

Peng, Zhiyi ^{[35
]}

Qian, Yeben ^{[36
]}

Ren, Wanhua ^{[37
]}

Shi, Jie ^{[3
]}

Song, Yusheng ^{[38
]}

Tao, Min ^{[39
]}

Tie, Jun ^{[40
,41
]}

Wan, Xueying ^{[42
]}

Wang, Bin ^{[43
]}

Wang, Jin ^{[44
]}

Wang, Kai ^{[45
]}

Wang, Kang ^{[3
]}

Wang, Xin ^{[2
,46
]}

机构：

[1] Sichuan Univ, West China Hosp, Canc Ctr, Dept Med Oncol, Chengdu, Peoples R China

[2] Sichuan Univ, West China Hosp, Canc Ctr, Div Abdominal Tumor Multimodal Treatment, Chengdu, Peoples R China

[3] Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 6, Shanghai, Peoples R China

[4] Chinese Acad Med Sci & Peking Union Med, Dept Hepatobiliary Surg, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China

[5] Sun Yat Sen Univ, Dept Liver Surg, Canc Ctr, Guangzhou, Peoples R China

[6] Beijing Tsinghua Changgung Hosp, Dept Radiol, Beijing, Peoples R China

[7] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Beijing, Peoples R China

[8] Sichuan Univ, West China Hosp, Liver Transplantat Ctr, Chengdu, Sichuan, Peoples R China

[9] Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Shanghai, Peoples R China

[10] Fujian Med Univ, Fujian Prov Canc Hosp, Teaching Hosp, Dept Abdominal Surg, Fuzhou, Peoples R China

[11] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Surg, Wuhan, Peoples R China

[12] China Med Univ, Affiliated Shengjing Hosp, Shenyang, Peoples R China

[13] Southern Med Univ, Sichuan Prov Peoples Hosp, Canc Ctr, Chengdu, Peoples R China

[14] Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 4, Shanghai, Peoples R China

[15] Sixth Peoples Hosp Shenyang, Dept Infect Dis, Shenyang, Peoples R China

[16] Southern Univ Sci & Technol, Peoples Hosp 3, Affiliated Hosp 2, Natl Clin Res Ctr Infect Dis, Shenzhen, Peoples R China

[17] Zhejiang Univ, Sch Med, Dept Radiol, Hangzhou, Peoples R China

[18] Chinese Peoples Liberat Army Gen Hosp, Comprehens Liver Canc Ctr, Med Ctr 5, Beijing, Peoples R China

[19] First Affiliated Hosp Anhui Med Univ, Dept Gen Surg, Hefei, Anhui, Peoples R China

[20] Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Radiol, Shanghai, Peoples R China

[21] Zhejiang Shuren Univ, Shulan Hangzhou Hosp, Shulan Int Med Coll, Dept Infect Dis, Hangzhou, Peoples R China

[22] Wuhan Univ, Renmin Hosp, Dept Clin Oncol, Wuhan, Peoples R China

[23] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Infect Dis, Xian, Peoples R China

[24] Shanxi Med Univ, Hosp 3, Shanxi Bethune Hosp, Shanxi Acad Med Sci,Dept Hepatobiliary Surg, Taiyuan, Peoples R China

[25] First Affiliated Hosp Soochow Univ, Dept Hematol, Dept Gastroenterol, Shanghai, Peoples R China

[26] Univ Sci & Technol China, Affiliated Hosp 1, Dept Gen Surg, USTC, Hefei, Peoples R China

[27] Zhuji Peoples Hosp Zhejiang Prov, Dept Hepatobiliary Surg, Zhuji, Peoples R China

[28] KMUST, Peoples Hosp Yunnan Prov 1, Dept Hepatobiliary & Pancreat Surg, Kunming, Peoples R China

[29] Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Rehabil Med, Sch Med,Dept Med Oncol, Shanghai, Peoples R China

[30] Beijing Tsinghua Changgung Hosp, Dept Radiat Oncol, Beijing, Peoples R China

[31] Kunming Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Kunming, Peoples R China

[32] Shandong Univ, Qilu Hosp, Dept Gen Surg, Jinan, Peoples R China

[33] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Canc Ctr, Chengdu, Peoples R China

[34] Sun Yat Sen Univ, Beijing, Peoples R China

[35] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Radiol, Hangzhou, Peoples R China

[36] Anhui Med Univ, Affiliated Hosp 1, Dept Gen Surg, Hefei, Peoples R China

[37] Shandong First Med Univ, Shandong Prov Hosp, Dept Infect Dis, Jinan, Shandong, Peoples R China

[38] Naval Med Univ, Dept Intervent Radiol, Shanghai, Peoples R China

[39] Soochow Univ, Affiliated Hosp 1, Dept Oncol, Suzhou, Peoples R China

[40] University, Xijing Hosp, Natl Clin Res Ctr Digest Dis, State Key Lab Canc Biol, Xian, Peoples R China

[41] Air Force Mil Med Univ, Xijing Hosp Digest Dis, Xijing Hosp, Xian, Peoples R China

[42] Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Chinese Tradit Med, Shanghai, Peoples R China

[43] Wuhan Univ, Renmin Hosp, Dept Hepatobiliary Surg, Wuhan, Peoples R China

[44] Third Affiliated Hosp Kunming Med Univ, Yunnan Canc Hosp, Kunming, Peoples R China

[45] Nanchang Univ, Affiliated Hosp 2, Dept Gen Surg, Hepatobiliary Pancreat Surg Div, Nanchang, Peoples R China

[46] Fifth Med Ctr Chinese PLA Gen Hosp, Dept Oncol, Beijing, Peoples R China

[47] Taiyuan Peoples Hosp, Dept Gen Surg, Taiyuan, Peoples R China

[48] Guangxi Med Univ, Canc Hosp, Dept Hepatobiliary Surg, Nanning, Peoples R China

[49] Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Oncol, Shanghai, Peoples R China

[50] Zhejiang Univ, Sch Med, Div Hepatobiliary Pancreat Surg, Beijing 310003, Peoples R China

来源：

LIVER CANCER | 2024年

基金：

中国国家自然科学基金;

关键词：

Hepatocellular carcinoma; Surgery; Surveillance; Systemic chemotherapy; Treatment; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; ATEZOLIZUMAB PLUS BEVACIZUMAB; VEIN TUMOR THROMBUS; OPEN-LABEL; PORTAL-VEIN; TRANSARTERIAL CHEMOEMBOLIZATION; INFUSION CHEMOTHERAPY; 1ST-LINE TREATMENT; RADIATION-THERAPY; CLINICAL-PRACTICE;

D O I：

10.1159/000541622

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in China. Most HCC patients have the complications of chronic liver disease and need overall consideration and whole-course management, including diagnosis, treatment, and follow-up. To develop a reasonable, long-term, and complete management plan, multiple factors need to be considered, including the patient's general condition, basic liver diseases, tumor stage, tumor biological characteristics, treatment requirements, and economic cost. Summary: To better guide the whole- course management of HCC patients, the Chinese Association of Liver Cancer and the Chinese Medical Doctor Association has gathered multidisciplinary experts and scholars in relevant fi elds to formulate the " Chinese Expert Consensus on The Whole-Course Management of Hepatocellular Carcinoma (2023)." Key Messages: This expert consensus, based on the current clinical evidence and experience, proposes surgical and nonsurgical HCC management pathways and involves 18 recommendations, including perioperative treatment, systematic treatment combined with local treatment, conversion treatment, special population management, symptomatic support treatment, and follow-up management. (c) 2024 The Author(s).

引用

页数：23

共 144 条

[1] Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma [J].

Abou-Alfa, G. K. ;

Meyer, T. ;

Cheng, A. -L. ;

El-Khoueiry, A. B. ;

Rimassa, L. ;

Ryoo, B. -Y. ;

Cicin, I. ;

Merle, P. ;

Chen, Y. H. ;

Park, J. -W. ;

Blanc, J. -F. ;

Bolondi, L. ;

Klumpen, H. -J. ;

Chan, S. L. ;

Zagonel, V. ;

Pressiani, T. ;

Ryu, M. -H. ;

Venook, A. P. ;

Hessel, C. ;

Borgman-Hagey, A. E. ;

Schwab, G. ;

Kelley, R. K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :54-63

[2]

Abou-Alfa Ghassan K, 2022, NEJM Evid, V1, pEVIDoa2100070, DOI 10.1056/EVIDoa2100070

[3] EASL Clinical Practice Guidelines: Drug-induced liver injury [J].

Andrade, Raul J. ;

Aithal, Guruprasad P. ;

Bjornsson, Einar S. ;

Kaplowitz, Neil ;

Kullak-Ublick, Gerd A. ;

Karlsen, Tom H. .

JOURNAL OF HEPATOLOGY, 2019, 70 (06) :1222-1261

[4] External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline [J].

Apisarnthanarax, Smith ;

Barry, Aisling ;

Cao, Minsong ;

Czito, Brian ;

DeMatteo, Ronald ;

Drinane, Mary ;

Hallemeier, Christopher L. ;

Koay, Eugene J. ;

Lasley, Foster ;

Meyer, Jeffrey ;

Owen, Dawn ;

Pursley, Jennifer ;

Schaub, Stephanie K. ;

Smith, Grace ;

Venepalli, Neeta K. ;

Zibari, Gazi ;

Cardenes, Higinia .

PRACTICAL RADIATION ONCOLOGY, 2022, 12 (01) :28-51

[5] Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors [J].

Arita, Junichi ;

Ichida, Akihiko ;

Nagata, Rihito ;

Mihara, Yuichiro ;

Kawaguchi, Yoshikuni ;

Ishizawa, Takeaki ;

Akamatsu, Nobuhisa ;

Kaneko, Junichi ;

Hasegawa, Kiyoshi .

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2022, 29 (07) :732-740

[6] Bridging treatment prior to liver transplantation for hepatocellular carcinoma: radioembolization or transarterial chemoembolization? [J].

Benkoe, Tamas ;

Koenig, Julia ;

Theysohn, Jens M. ;

Schotten, Clemens ;

Saner, Fuat H. ;

Treckmann, Juergen ;

Radunz, Sonia .

EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2022, 27 (01)

[7] Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Bruix, Jordi ;

Qin, Shukui ;

Merle, Philippe ;

Granito, Alessandro ;

Huang, Yi-Hsiang ;

Bodoky, Gyrogy ;

Pracht, Marc ;

Yokosuka, Osamu ;

Rosmorduc, Olivier ;

Breder, Valeriy ;

Gerolami, Rene ;

Masi, Gianluca ;

Ross, Paul J. ;

Song, Tianqiang ;

Bronowicki, Jean-Pierre ;

Ollivier-Hourmand, Isabelle ;

Kudo, Masatoshi ;

Cheng, Ann-Lii ;

Llovet, Josep M. ;

Finn, Richard S. ;

LeBerre, Marie-Aude ;

Baumhauer, Annette ;

Meinhardt, Gerold ;

Han, Guohong .

LANCET, 2017, 389 (10064) :56-66

[8] Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma [J].

Catalano, Martina ;

Casadei-Gardini, Andrea ;

Vannini, Gianmarco ;

Campani, Claudia ;

Marra, Fabio ;

Mini, Enrico ;

Roviello, Giandomenico .

EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021, 14 (11) :1353-1365

[9] Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma [J].

Chami, Perla ;

Diab, Youssef ;

Khalil, Danny N. ;

Azhari, Hassan ;

Jarnagin, William R. ;

Abou-Alfa, Ghassan K. ;

Harding, James J. ;

Hajj, Joseph ;

Ma, Jennifer ;

El Homsi, Maria ;

Reyngold, Marsha ;

Crane, Christopher ;

Hajj, Carla .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (23)

[10] Multidisciplinary Taiwan consensus for the use of conventional TACE in hepatocellular carcinoma treatment [J].

Chang, Pi-Yi ;

Lee, Rheun-Chuan ;

Liang, Po-Chin ;

Liu, Yi-Sheng ;

Chuang, Vicent P. ;

Wu, Ding-Kwo ;

Cheng, Yu-Fan ;

Huang, Jen-I. ;

Tseng, Hsiuo-Shan ;

Hung, Chien-Fu ;

Wu, Reng-Hong ;

Chern, Ming-Chih ;

Cheng, Hua-Ming ;

Wu, Chih-Horng ;

Cheng, She-Meng ;

Chiang, Chia-Ling ;

Liang, Huei-Lung .

FRONTIERS IN ONCOLOGY, 2023, 13

← 1 2 3 4 5 6 7 8 9 10 →